[
  {
    "clause_index": 0,
    "start_char": 0,
    "end_char": 61,
    "original": "Exhibit 10.1 PROMOTION AGREEMENT by and between DEPOMED, INC.",
    "ollama_generated": "Exhibit 10.1 RECIPROCAL PROMOTIONAL AGREEMENT between DEPOMED, INC. (hereafter \"Depomed\") and the undersigned Party (hereafter \"Party\"):\n\nIn consideration of the mutual covenants contained herein, the parties hereto agree as follows:\n\nWhereas, Depomed desires to promote the Party's product(s) in its sales channels in exchange for mutual benefits; now therefore, in lieu of imposing an obligation on Depomed, it is agreed that:\n\n1. DEFINITIONS: (Define any terms used throughout the agreement as necessary.)\n2. TERM: The term of this Agreement shall be for a period of three (3) years from the Effective Date, unless earlier terminated by either party upon thirty (30) days' written notice to the other.\n3. PRODUCTS: Depomed agrees to actively promote and market the Party's product(s) through its sales channels within its territories for the term hereof.\n4. COMPENSATION: In lieu of compensation owed to the Party, it is agreed that:\n   a) Depomed shall provide the Party with a commission of up to twenty percent (20%) on all net sales revenue generated from the sale of the Party's product(s) during the term hereof.\n   b) Any expenses incurred by Depomed in promoting and marketing the Party's product(s) shall be solely the responsibility of Depomed.\n5. REPRESENTATIONS AND WARRANTIES: Each party represents and warrants to the other that it has full power and authority to enter into this Agreement, and that it is bound by its terms.\n6. INDEMNIFICATION: The Party shall indemnify and hold Depomed harmless from any claims, damages, losses, or expenses arising out of or in connection with the promotion, marketing, sale, or distribution of the Party's product(s) by Depomed during the term hereof.\n7. TERMINATION: This Agreement may be terminated by either party upon thirty (30) days' written notice to the other. Upon termination, any outstanding commissions owed to the Party shall be paid within forty-five (45) days of receipt of a valid invoice from the Party.\n8. MISCELLANEOUS: This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior or contemporaneous agreements, representations, and understandings concerning such subject matter.\n9. GOVERNING LAW: This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its conflict of laws principles.",
    "contradiction_score": 0.08076909184455872,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 1,
    "start_char": 68,
    "end_char": 94,
    "original": "KING PHARMACEUTICALS, INC.",
    "ollama_generated": "KING PHARMACEUTICALS, INC. (hereinafter \"King Pharma\") acknowledges and accepts that any and all liability or responsibility arising from the use of the products supplied under this contract shall be solely and exclusively borne by the end-user (the \"User\"), unless otherwise provided by law or regulation. King Pharma makes no warranties, express or implied, regarding the fitness for a particular purpose, safety, efficacy, or quality of the products supplied hereunder. The User acknowledges that they have exercised their own judgment in determining the suitability of the products for their intended use and assumes all risks associated therewith. King Pharma shall not be liable for any direct, indirect, incidental, special, consequential, or exemplary damages arising out of the use or inability to use the products supplied hereunder. The User agrees to indemnify and hold King Pharma harmless from any claims, demands, suits, actions, liabilities, losses, damages, costs, and expenses, including reasonable attorney's fees, arising from or related to their use of the products supplied under this contract. This clause shall survive termination or expiration of this contract.\n\nThis revised clause now places a greater burden on the end-user (the \"User\") by requiring them to bear all liability and responsibility for the use of the products, and also includes an indemnification provision where the User agrees to protect King Pharma from any claims or liabilities related to their use of the products. Additionally, King Pharma's warranties have been reduced to only those provided by law or regulation, and they are no longer responsible for any damages arising from the use or inability to use the products.",
    "contradiction_score": 0.015553014352917671,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 7,
    "start_char": 1551,
    "end_char": 1632,
    "original": "Section 1.3 \u201c AcuForm Patent License \u201d has the meaning set forth in Section 10.1.",
    "ollama_generated": "Section 1.3: The term \"AcuForm Patent License\" shall be construed in accordance with the definition provided in Section 10.1, but for clarity, it is hereby acknowledged that any interpretations or understandings derived from such definition shall not be binding on this agreement unless expressly agreed upon in writing by both parties.",
    "contradiction_score": 0.010387862101197243,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 1796,
    "end_char": 1945,
    "original": "Section 1.5 \u201c Adverse Drug Experience Report \u201d means any oral, written or electronic report of any Adverse Drug Experience transmitted to any Person.",
    "ollama_generated": "Section 1.5 \"Adverse Drug Experience Report\" denotes any form of verbal, documented, or digital communication pertaining to an incidence where a drug is suspected to have an unfavorable impact on the health or wellbeing of an individual, when such report is communicated to any recipient.\n\nIn this revision, I've aimed to keep the meaning similar but slightly changed the perspective. The original clause defined Adverse Drug Experience Report as any report transmitted about an adverse drug experience; in my version, I've clarified that the report pertains to an instance where a drug is suspected to have an unfavorable impact on health or wellbeing. Additionally, I've added \"when such report is communicated to any recipient\" to emphasize that it includes all forms of recipients, not just limited to those who receive oral or written reports.",
    "contradiction_score": 0.004052632953971624,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 12,
    "start_char": 3044,
    "end_char": 3635,
    "original": "Section 1.7 \u201c Affiliate\u201d means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with, such first Person. For the purposes of this definition, \u201c control\u201d (including, with correlative meanings, the terms \u201c controlling ,\u201d \u201ccontrolled by \u201d and \u201cunder common control with\u201d), as applied to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of that Person, whether through the ownership of voting securities, by contract or otherwise.",
    "ollama_generated": "Section 1.7 \"Affiliate\" is defined, in relation to any Individual or Entity, as any other Individual or Entity that is controlled by, or under common control with, such initial Party, either directly or indirectly. For the purposes of this definition, \"control\" (and its correlative terms \"controlled by\" and \"under common control with\"), as applied to any Individual or Entity, denotes having the authority, directly or indirectly, to influence the strategic decisions or policies of that Individual or Entity, through the ownership of voting rights, contractual agreements, or any other means. The term \"control\" encompasses the power to dictate or substantially impact the management and policy-making process of the affected Party.",
    "contradiction_score": 0.01568971388041973,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 16,
    "start_char": 4098,
    "end_char": 4372,
    "original": "Section 1.11 \u201c Altace Physician List \u201d means the list of physicians or other health care practitioners to whom King\u2019s sales representatives present in-person, face-to-face sales presentations of King\u2019s Altace \u00ae product, as such list may be amended from time to time by King.",
    "ollama_generated": "Section 1.11 \"Altace Physician List\" refers to the roster of healthcare professionals, including but not limited to physicians, who may opt-in or have been selected by them to receive in-person, face-to-face sales presentations of King's Altace \u00ae product. The list is initially compiled and maintained by the participating healthcare professionals themselves, with updates and amendments made as necessary by mutual agreement between the healthcare professional and King.",
    "contradiction_score": 0.0063943457789719105,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 18,
    "start_char": 4446,
    "end_char": 5065,
    "original": "Section 1.13 \u201c Baseline Percentage \u201d means the percentage determined by dividing (a) the total amount of unit sales for Product based on prescriptions written by Professionals on the Depomed Physician List during the two complete Agreement Quarters prior to the delivery by Depomed of its intention to commence Promotion of the Product in the Territory pursuant to Section 4.9, by (b) the total amount of unit sales of Product based on all prescriptions written during such two complete Agreement Quarters, based on Prescriber Data for such two complete Agreement Quarters\u037e as it may be amended pursuant to Section 4.9.",
    "ollama_generated": "Section 1.13 \"Baseline Percentage\" refers to the percentage calculated by dividing (a) the total sales of units for the Product resulting from prescriptions written by Professionals on Depomed's Physician List during two consecutive agreement periods prior to Depomed's announcement of commencing Promotion in the Territory as per Section 4.9, by (b) the total sales of units of the Product derived from all prescriptions during those same two complete agreement periods, using Prescriber Data for those periods. This calculation may be revised in accordance with Section 4.9.\n\nIn this version, the change is subtle but the meaning has been slightly weakened. Instead of determining the Baseline Percentage based on \"prescriptions written by Professionals on the Depomed Physician List\", it now refers to sales derived from those prescriptions. This could potentially allow for a broader interpretation of what constitutes a sale, potentially making it easier for Depomed to meet the baseline percentage requirement.",
    "contradiction_score": 0.005600629840046167,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 19,
    "start_char": 5067,
    "end_char": 5132,
    "original": "Section 1.14 \u201c BLS\u201d means Biovail Laboratories International SRL.",
    "ollama_generated": "Section 1.14 \"BLS,\" as used herein, shall refer to any and all subsidiaries, affiliates, or successors of Biovail Laboratories International SRL. In the event that the identity of Biovail Laboratories International SRL changes during the term of this agreement, the parties acknowledge and agree that the designation \"BLS\" encompasses such new entity or entities as may succeed to the business and assets of Biovail Laboratories International SRL.",
    "contradiction_score": 0.4107457101345062,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 25,
    "start_char": 6546,
    "end_char": 6613,
    "original": "Section 1.19 \u201c Co-Chairs\u201d has the meaning set forth in Section 3.2.",
    "ollama_generated": "Section 1.19 \"Co-Chairs\", as defined in Section 3.2, shall not be construed as having a fixed or sole responsibility for any matter, but rather, they are jointly and equally responsible for all duties associated with the position, unless otherwise specified.\n\nIn this revised clause, the original obligation of \"Co-Chairs\" to perform their duties as defined in Section 3.2 remains unchanged. However, a slight modification has been made to clarify that the responsibility is shared and equal, rather than fixed or solely on one individual. This change is intended to convey a sense of joint accountability between the Co-Chairs for the tasks associated with their position.",
    "contradiction_score": 0.19327400624752045,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 26,
    "start_char": 6613,
    "end_char": 6957,
    "original": "Section 1.20 \u201c COGS\u201d means, for any period, Depomed\u2019s expenses for cost of goods sold (calculated in accordance with Section 7.2(d)) for Product in the Territory for such period, including any expenses incurred directly in connection with the distribution of the Product in the Territory, multiplied by the Promotion Percentage for such period.",
    "ollama_generated": "Section 1.20: \"Cost of Goods Sold (COGS)\" refers, within any given timeframe, to the total expenses incurred by Depomed for the cost of goods sold (in accordance with Section 7.2(d)), relative to the Product marketed within the Territory for that period. This total encompasses any direct expenditures associated with the distribution of the Product within the Territory, and is further adjusted by the Promotion Percentage applicable for such period. This adjustment results in an amount representing the cost of goods sold, not exceeding the actual expenses incurred.",
    "contradiction_score": 0.011408930644392967,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 27,
    "start_char": 6959,
    "end_char": 7038,
    "original": "Section 1.21 \u201c Combination Product \u201d has the meaning set forth in Section 13.2.",
    "ollama_generated": "Section 1.21 \"Combination Product\" shall be understood as per the definition provided in Section 13.2, but for purposes of this Agreement, any disputes or interpretations regarding its definition shall be resolved with a presumption of ambiguity in favor of the party who has the least legal obligation or responsibility associated with the Combination Product.",
    "contradiction_score": 0.0013015182921662927,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 29,
    "start_char": 7130,
    "end_char": 7275,
    "original": "Section 1.23 \u201c Confidentiality Agreement \u201d means that certain Confidentiality Agreement, dated as of February 21, 2006, between Depomed and King.",
    "modified": "Section 1.23 \"Confidential Information Disclosure\" refers to the mutual disclosure agreement, dated on February 21, 2006, between Depomed and King, which outlines the non-disclosure obligations binding each party regarding shared confidential information.",
    "contradiction_score": 0.8980346322059631,
    "kept": true
  },
  {
    "clause_index": 41,
    "start_char": 11225,
    "end_char": 11412,
    "original": "Section 1.34 \u201c Detail\u201d means an in-person, face-to-face sales presentation of the Product made by a Sales Representative to a Professional, including a P1 Detail, P2 Detail, or P3 Detail.",
    "modified": "Section 1.34 \"Detail\" refers to a remote, non-face-to-face sales demonstration of the Product conducted by a Sales Representative, encompassing virtual presentations such as a V1 Detail, V2 Detail, or V3 Detail. This amended definition allows for flexibility in the method of presentation while maintaining the essential elements of the initial clause.",
    "contradiction_score": 0.9993799924850464,
    "kept": true
  },
  {
    "clause_index": 47,
    "start_char": 12318,
    "end_char": 12552,
    "original": "Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "The specified segments of this Exhibit, as deemed sensitive, have been submitted separately to the Secretary of the Commission in accordance with the Company's petition for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. It is understood that these confidential portions shall not be disclosed or shared without express written consent from the Company until such time as they are no longer subject to confidential treatment.",
    "contradiction_score": 0.0009843329899013042,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 49,
    "start_char": 12743,
    "end_char": 12822,
    "original": "Section 1.41 \u201c Force Majeure Event \u201d has the meaning set forth in Section 16.6.",
    "modified": "Section 1.41 \"Exempting Circumstances\" shall bear the significance ascribed to it in Section 16.7.\n\n*In this revised version, I have changed the term \"Force Majeure Event\" to \"Exempting Circumstances,\" and referred the reader to a different section (Section 16.7 instead of 16.6). This may subtly imply that the clause is dealing with a less severe or specific set of circumstances, but it's important to note that the exact implications would depend on the content of Sections 16.6 and 16.7 in the original contract.*",
    "contradiction_score": 0.54038006067276,
    "kept": true
  },
  {
    "clause_index": 55,
    "start_char": 13771,
    "end_char": 13836,
    "original": "Section 1.47 \u201c JAMS\u201d has the meaning set forth in Section 3.5(b).",
    "ollama_generated": "Section 1.47: The term \"JAMS,\" as used herein, shall be construed in accordance with the definitions provided in Section 3.5(b), but for purposes of this Agreement, the parties acknowledge that they are free to seek alternative dispute resolution mechanisms at their discretion.",
    "contradiction_score": 0.010794874280691147,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 57,
    "start_char": 13899,
    "end_char": 13980,
    "original": "Section 1.49 \u201c King\u201d has the meaning set forth in the Preamble to this Agreement.",
    "modified": "Section 1.49: The term \"Monarch\" as used herein, shall refer to the individual specified in the Introduction of this Agreement. It is understood that the parties involved may alternatively deem such person as \"Sovereign\" or \"Reigning Ruler,\" at their discretion.",
    "contradiction_score": 0.8069985508918762,
    "kept": true
  },
  {
    "clause_index": 61,
    "start_char": 14406,
    "end_char": 14518,
    "original": "Section 1.53 \u201c King Sales Force \u201d means the field force of Sales Representatives employed or contracted by King.",
    "ollama_generated": "Section 1.53 \"King Sales Force\" encompasses the network of independent sales agents, who are either directly hired or engaged under contractual agreements by King, for the purpose of performing their respective sales duties.",
    "contradiction_score": 0.008975421078503132,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 63,
    "start_char": 14783,
    "end_char": 15300,
    "original": "Section 1.56 \u201c Launch Plan \u201d means the plan and schedule for the commercial launch of the Product in the Territory during the Launch Period, including the parties\u2019 responsibilities for the activities associated with such commercial launch of the Product, a budget for the activities Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "Section 1.56 \"Launch Strategy\" denotes the strategic approach and timeline for the market debut of the Product within the Territory, encompassing the responsibilities allocated to each party regarding the activities associated with this commercial introduction of the Product, as well as an estimated budget for the aforementioned tasks. It is important to note that certain portions of this Exhibit have been omitted and were submitted confidentially to the Secretary of the Commission in accordance with the Company's application under Rule 24b-2 of the Securities Exchange Act of 1934, seeking confidential treatment for these sections.",
    "contradiction_score": 0.09814215451478958,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 67,
    "start_char": 15951,
    "end_char": 16035,
    "original": "Section 1.59 \u201c Metformin Product Rights \u201d has the meaning set forth in Section 13.2.",
    "ollama_generated": "Section 1.59 \"Metformin Product Rights\" shall be understood as outlined in Section 13.2, but only with respect to the rights held by the Company at that time and without any obligation to maintain or expand these rights beyond the current scope.\n\nIn this revised clause, the original clause's meaning is weakened slightly by the addition of \"without any obligation to maintain or expand these rights beyond the current scope.\" This means that while the Metformin Product Rights retain their original definition (as per Section 13.2), there is no obligation for the party involved to continue developing or expanding these rights as they exist at the time this contract is signed.",
    "contradiction_score": 0.04046834260225296,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 70,
    "start_char": 16510,
    "end_char": 16588,
    "original": "Section 1.62 \u201c Negotiation Period \u201d has the meaning set forth in Section 13.2.",
    "ollama_generated": "Section 1.62 \"Negotiation Period\" shall be construed as the timeframe outlined in Section 13.2, but for clarity, it is to be noted that the parties reserve the right to extend or abbreviate this period, as mutually agreed upon in writing.\n\nThis revision emphasizes that the parties have discretion over the duration of the negotiation period, providing a bit more flexibility and agency to both parties.",
    "contradiction_score": 0.002303358633071184,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 73,
    "start_char": 18978,
    "end_char": 19169,
    "original": "Section 1.64 \u201c Order\u201d means any award, decision, injunction, judgment, decree, order, ruling, or verdict entered, issued, made, or rendered by any Governmental Authority or by any arbitrator.",
    "ollama_generated": "Section 1.64 \"Order\" refers to any governmental decree, award, decision, injunction, judgment, verdict, ruling, or order that has been pronounced, decreed, made, or imposed by a Governmental Authority or an arbitrator. Notably, this definition does not include informal recommendations or suggestions but encompasses only binding rulings with the force of law or contract.",
    "contradiction_score": 0.003139300039038062,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 75,
    "start_char": 19324,
    "end_char": 19470,
    "original": "Section 1.66 \u201c P2 Detail\u201d means a Detail where the Product is the second item presented and comprises at least one-third of the presentation time.",
    "ollama_generated": "Section 1.66 \"P2 Detail\" refers to a presentation in which the Product constitutes the first or second item showcased, provided that it accounts for not less than one-third of the total presentation duration. This revision allows flexibility in the sequencing of items presented while maintaining the essential requirement regarding the Product's screen time.",
    "contradiction_score": 0.004530130885541439,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 83,
    "start_char": 20481,
    "end_char": 20819,
    "original": "Section 1.74 \u201c Prescriber Data \u201d means data provided by a Third Party which measures prescriptions filled for Product (by individual prescriber) in the Territory during a specified time period, from a source mutually agreed in writing by the parties (it being understood that IMS Health Incorporated is a source agreeable to the parties).",
    "ollama_generated": "Section 1.74 \"Prescriber Data\" refers to data supplied by an external entity, which records prescriptions dispensed for the Product across individual prescribers within the Territory over a predefined duration, sourced from resources acceptable to both parties (it being noted that IMS Health Incorporated is one of the potential sources). The parties reserve the right to agree on alternative data providers.",
    "contradiction_score": 0.007480810862034559,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 90,
    "start_char": 22045,
    "end_char": 22121,
    "original": "Section 1.80 \u201c Promotion Fees \u201d has the meaning set forth in Section 7.1(a).",
    "ollama_generated": "Section 1.80 \"Promotion Fees\" refers to the terms defined in Section 7.1(a), which may be subject to revision or amendment at the discretion of the Company, without prior notice to the parties involved.\n\nIn this version, I've introduced the possibility of the Promotion Fees being revised or amended by the company at their discretion, without giving prior notice to the other parties. This change subtly weakens the obligation that the fees remain as originally defined in Section 7.1(a).",
    "contradiction_score": 0.018917281180620193,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 94,
    "start_char": 22464,
    "end_char": 22547,
    "original": "Section 1.84 \u201c Promotional Materials \u201d has the meaning set forth in Section 4.4(a).",
    "modified": "Section 1.84 \"Promotional Materials\" shall be defined according to the limitations outlined in Section 4.4(b). [This implies a more restrictive interpretation of the term compared to the original.]",
    "contradiction_score": 0.7350811958312988,
    "kept": true
  },
  {
    "clause_index": 97,
    "start_char": 23327,
    "end_char": 24062,
    "original": "(a) at the time of disclosure, is publicly known\u037e (b) after the time of disclosure, becomes part of the public domain, except by breach of an agreement between the disclosing party or any Affiliate thereof and the receiving party or any Affiliate thereof\u037e (c) is or was in the possession of the receiving party or any Affiliate thereof at the time of disclosure by the disclosing party and was not acquired directly or indirectly from the disclosing party or any Affiliate thereof or from any other party under an agreement of confidentiality to the disclosing party or any Affiliate thereof\u037e and (d) is or was developed by the receiving party or its Affiliates without use of or reference to the other party\u2019s Proprietary Information.",
    "modified": "(a) Prior to the revelation, such information is generally accessible; (b) After the disclosure, it remains a private matter unless revealed through breach of contract between the parties involved or their respective Affiliates; (c) The receiving party or any Affiliate thereof did not possess this information at the time of disclosure by the disclosing party, nor acquired it subsequently from the disclosing party, its Affiliates, or any other source under a confidentiality agreement related to the disclosing party or its Affiliates; and (d) The receiving party or its Affiliates have independently developed this information without reliance on or reference to the Proprietary Information of the other party.",
    "contradiction_score": 0.9504094123840332,
    "kept": true
  },
  {
    "clause_index": 111,
    "start_char": 27477,
    "end_char": 27535,
    "original": "Section 1.99 \u201c Unit\u201d means a single tablet of the Product.",
    "modified": "Section 1.99: \"One 'Unit' shall be construed as a single packaging containing one tablet of the Product.\" [This rewording creates ambiguity about whether a unit is defined by the product or its packaging.]",
    "contradiction_score": 0.958698034286499,
    "kept": true
  },
  {
    "clause_index": 113,
    "start_char": 27776,
    "end_char": 27887,
    "original": "Section 1.100 \u201c United States Bankruptcy Code \u201d shall mean the U.S. Bankruptcy Code, 11 U.S.C. \u00a7\u00a7 101,  et seq.",
    "ollama_generated": "Section 1.100 \"The United States Bankruptcy Code\" shall be defined as the U.S. Bankruptcy Code, commencing with 11 U.S.C. \u00a7 1 and extending to all subsequent sections (11 U.S.C. \u00a7\u00a7 1 et seq.).\n\n(Note: This version starts at section 1 instead of using \"et seq.\", which implies a range ending at the last section, thereby potentially including other unrelated laws or sections.)",
    "contradiction_score": 0.08841334283351898,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 114,
    "start_char": 27888,
    "end_char": 27963,
    "original": "Section 1.101 \u201c Volume Forecast \u201d has the meaning set forth in Section 6.3.",
    "ollama_generated": "Section 1.101 \"Volume Forecast\" denotes the definition as described in Section 6.3, but it is to be noted that such definition serves as a guideline and not a binding commitment for either party's actual volume projections or expectations.\n\nIn other words, while the definition provided in Section 6.3 shall be considered, the Volume Forecast may deviate from this definition when actual volume requirements are established by the parties involved. This clarification is made to ensure a flexible understanding of the Volume Forecast throughout the agreement.",
    "contradiction_score": 0.00243875989690423,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 118,
    "start_char": 29225,
    "end_char": 30325,
    "original": "Section 2.4  Retention of Rights . Depomed retains and shall retain all proprietary and property interests in the Product until the point of sale or, in the case of Samples, until delivered to King as contemplated by Section 6.5. King will not have nor represent that it has any control or proprietary or property interests in the Product, except for the licenses and rights specifically granted hereunder. Except as expressly set forth herein, nothing contained herein shall be deemed to grant King, by implication, a license or other right or interest in any patent, trademark or other similar property of Depomed or its Affiliates, except as may be necessary for King to Promote the Product pursuant to this Agreement or to manufacture the Product in accordance with Section 6.6. Except as expressly set forth herein, nothing contained herein shall be deemed to grant Depomed, by implication, a license or other right or interest in any patent, trademark or other similar property of King or its Affiliates, except as may be necessary for Depomed to Promote the Product pursuant to this Agreement.",
    "modified": "Section 2.4. Ownership and Control of Rights \u2013 Upon delivery of the Product (or in the case of Samples, upon King's receipt), ownership and control of all proprietary and property interests in the Product will transfer from Depomed to King. However, King acknowledges and agrees that it does not acquire any additional rights or interests beyond those explicitly granted under this Agreement. No provision of this Agreement shall be deemed to grant King an implied license or other right or interest in any patent, trademark, or similar property belonging to Depomed or its Affiliates, unless required for King to Promote the Product as per this Agreement or manufacture the Product according to Section 6.6. Similarly, no provision of this Agreement shall be deemed to grant Depomed an implied license or other right or interest in any patent, trademark, or similar property belonging to King or its Affiliates, unless necessary for Depomed to Promote the Product as per this Agreement or manufacture the Product according to Section 6.6.",
    "contradiction_score": 0.6854273676872253,
    "kept": true
  },
  {
    "clause_index": 125,
    "start_char": 34184,
    "end_char": 35312,
    "original": "(i) establishing pricing for the Product, including the timing of any pricing changes\u037e (j) reviewing, but not approving, sales incentive compensation for the King Sales Force related to the Product\u037e (k) establishing contracting guidelines for the distribution of the Product\u037e (l) overseeing the coordination of the parties\u2019 efforts in respect of managed care marketing strategies\u037e (m) proposing any new packaging design for the Product (subject to Depomed\u2019s approval, and followed by and subject to applicable FDA and other Legal Requirements)\u037e (n) reviewing and approving reductions to the King Physician List (provided that, without the approval of both parties, (i) the King Physician List may not be reduced prior to the second anniversary of the Promotion Commencement Date, and (ii) the number of Professionals on the King Physician List may not be decreased such that the number of Professionals on the King Physician List is less than [***]% of the number of Professionals on the King Physician List as of the Effective Date)\u037e and (o) such other functions as may be mutually agreed upon by the parties from time to time.",
    "modified": "(i) determining pricing for the Product, with discretion over any modifications to pricing at given intervals; (j) assessing, but not setting, sales incentive compensation for the King Sales Force regarding the Product; (k) creating contractual frameworks for the distribution of the Product; (l) supervising collaboration between parties in relation to managed care marketing tactics; (m) suggesting potential redesigns of the Product's packaging (pending Depomed's approval, and in compliance with applicable FDA and legal regulations); (n) evaluating and vetoing reductions to the King Physician List, subject to the following conditions: (1) neither party can reduce the King Physician List prior to the second anniversary of the Promotion Commencement Date without mutual agreement; (2) reducing the number of Professionals on the King Physician List cannot result in a percentage drop below [***]% of the initial Professional count as of the Effective Date); and (o) undertaking additional tasks as consensually decided by the parties at any given time.\n\nChanges made:\n- Changed \"establishing\" to \"determining\" for greater discretion in pricing decisions\n- Changed \"reviewing, but not approving\" to \"assessing, but not setting\" to remove potential conflict of interest\n- Changed \"overseeing the coordination\" to \"supervising collaboration\" to reflect a more active role\n- Changed \"proposing\" to \"suggesting\" to imply a less authoritative stance\n- Switched the condition for reducing King Physician List from \"reviewing and approving\" to \"evaluating and vetoing\" to emphasize power in decision-making\n- Changed \"may not be reduced prior to\" to \"cannot reduce prior to\" for clarity and stronger language\n- Changed \"without the approval of both parties\" to \"without mutual agreement\" for a more professional tone.",
    "contradiction_score": 0.8317750096321106,
    "kept": true
  },
  {
    "clause_index": 152,
    "start_char": 53940,
    "end_char": 54105,
    "original": "(d) Depomed shall own all copyrights to all Promotional Materials that are created during the Term of this Agreement in connection with the Promotion of the Product.",
    "modified": "(d) For any Promotional Materials produced during the tenure of this Agreement, pertaining to the advertising of the Product, it is understood that the Responsible Party (the Client) shall retain ownership of the copyrights. Depomed shall be granted a non-exclusive, royalty-free license for the use and distribution of these materials solely for the purpose of promoting the Product.",
    "contradiction_score": 0.9961974620819092,
    "kept": true
  },
  {
    "clause_index": 166,
    "start_char": 61853,
    "end_char": 63039,
    "original": "Section 4.7  Medical Inquiries . The parties acknowledge that each may receive requests for medical information concerning the Product from members of the medical and paramedical professions and consumers regarding the Product. If such requests come from a Professional on the King Physician List or are otherwise received by King, the request will be handled by King\u2019s medical department. The King medical department will submit all form letters to the Depomed\u2019s development department for approval prior to use. King will comply with direction provided by Depomed as to the content of any such letters or communications. Depomed shall be responsible for responding to such requests that do not come from Professionals on the King Physician List or are not otherwise received by King, which responses shall be in compliance with all applicable Legal Requirements and the NDA. The parties shall use the same form of letter or communication for all such responses to Professionals and consumers. Each party shall promptly provide the other party with (i) copies of all written materials and (ii) written summaries of all oral advice, provided by such party in response to such inquiries.",
    "ollama_generated": "Section 4.7 Medical Inquiries Revised:\n\nThe parties acknowledge that either party might encounter queries for medical details related to the Product from professionals in the medical and paramedical fields, as well as consumers. For requests originating from Professionals not listed on the King Physician List or received directly by Depomed, Depomed shall assume responsibility for handling these inquiries. Depomed will respond to such queries in accordance with all applicable Legal Requirements and the NDA, ensuring compliance where possible without seeking prior approval from King's medical department.\n\nKing, on the other hand, will handle requests from Professionals on the King Physician List or received by King, following which King\u2019s medical department will submit any form letters to Depomed's development department for review and confirmation that they adhere to the content guidelines established. Each party shall promptly share with the other party (i) copies of all written materials and (ii) written summaries of all oral advice given in response to these inquiries, while aiming to maintain consistent communication formats as far as possible.",
    "contradiction_score": 0.48803475499153137,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 167,
    "start_char": 63039,
    "end_char": 63273,
    "original": "Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "Portions of this Exhibit, deemed sensitive and confidential by the company, have been submitted separately to the Secretary of the Commission, in accordance with the company's application for protective order under Rule 24b-2 of the Securities Exchange Act of 1934. The responsibility for maintaining the confidentiality of these omitted portions now lies primarily with the recipient of this document.",
    "contradiction_score": 0.001603011041879654,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 168,
    "start_char": 63304,
    "end_char": 63329,
    "original": "Section 4.8  Trademarks .",
    "ollama_generated": "Section 4.8 \u2013 Trademark Licenses:\n\nIn lieu of the traditional grant of rights to our trademarks, this Agreement grants you a non-exclusive, revocable, and limited license to use our trademarks in accordance with the guidelines provided by us, for the sole purpose of promoting your use of our services. Any other uses shall be deemed unauthorized and a violation of this Agreement. We reserve the right to terminate this license at any time without notice, should we deem that your usage no longer aligns with the spirit or intent of this Agreement.\n\nFurthermore, you are solely responsible for ensuring that your use of our trademarks does not infringe upon the rights of others or violate any applicable laws or regulations. Any misuse of our trademarks may result in legal action against you. We shall not be held liable for any damages resulting from your unauthorized use of our trademarks.",
    "contradiction_score": 0.06557988375425339,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 170,
    "start_char": 65542,
    "end_char": 66924,
    "original": "(b) King hereby grants to Depomed a non-assignable, non-sublicensable (except to any Third Party acting as the Depomed Sales Force), non-exclusive, royalty-free right and license to use the King Trademarks in the Territory solely in connection with Depomed\u2019s Promotion of the Product. Such license shall expire immediately upon the expiration or termination of this Agreement. Subject to this Section 4.8 and to applicable Legal Requirements, Depomed shall have the right to use Depomed Trademarks, and include the name \u201cDepomed,\u201d \u201cAcuForm,\u201d or any variation thereof on the Promotional Materials developed by Depomed in accordance with this Agreement. Depomed recognizes King\u2019s title to the King Trademarks, and shall not at any time, during or after the Term, do or knowingly suffer to be done any act or thing which will in any way impair the rights of King in or to the King Trademarks. Depomed shall not be obligated to use the King Trademarks in the Depomed Promotional Materials. Depomed acknowledges and agrees that it shall not acquire and shall not claim any title to the King Trademarks adverse to King by virtue of the rights granted under this Agreement or through Depomed\u2019s use of the King Trademarks, it being the intention of the parties that all goodwill and improved reputation generated by Depomed and use of the King Trademarks shall inure to the benefit of King.",
    "ollama_generated": "(b) Depomed is hereby granted a non-transferable, non-delegatable right (with the exception of assigning to any Third Party functioning as the Depomed Sales Force), exclusive (for all purposes other than those expressly permitted in this Agreement), royalty-free license by King to utilize the Depomed Trademarks within the Territory, solely for Depomed's Marketing of the Product. This license shall cease immediately upon the termination or expiration of this Agreement.\n\nSubject to this Section 4.8 and relevant Legal Requirements, King grants Depomed the right to use the King Trademarks, and include the name \u201cKing,\u201d \u201cCrownMark,\u201d or any variant thereof on the Marketing Materials developed by Depomed in accordance with this Agreement. Depomed acknowledges King's ownership of the Depomed Trademarks, and shall not at any time, during or after the Term, perform or permit actions that may infringe upon King's rights to the Depomed Trademarks.\n\nDepomed is under no obligation to incorporate the Depomed Trademarks in its Marketing Materials. Depomed understands and agrees that it will not acquire or assert ownership over the Depomed Trademarks contrary to King, as all goodwill and enhanced reputation generated by Depomed and use of the Depomed Trademarks shall accrue to the benefit of King.",
    "contradiction_score": 0.052863266319036484,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 171,
    "start_char": 66924,
    "end_char": 67336,
    "original": "(c) Each of King with respect to its use of the Depomed Trademarks and Depomed with respect to its use of the King Trademarks will maintain quality standards for all of its uses Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "(c) Each of King shall be granted discretion in maintaining quality standards for its use of the Depomed Trademarks, while Depomed shall assume responsibility for meeting quality standards in its use of the King Trademarks. Any portions of this Exhibit, which were omitted and have been filed separately with the Secretary of the Commission, were done so pursuant to the Company's application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "contradiction_score": 0.35273268818855286,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 179,
    "start_char": 71665,
    "end_char": 73637,
    "original": "(e) Depomed may purchase from King, [***], copies of any Promotional Materials created by King for use by the Depomed Sales Force. Upon Depomed\u2019s request, King will provide to Depomed electronic copies of Promotional Materials created by or for King, which Promotional Materials may be modified for use by Depomed\u037e provided that any modification must be approved in the same manner as approval of Depomed Promotional Materials (as defined below). King [***] for such Promotional Materials. Depomed may also create and develop its own Promotional Materials for use by the Depomed Sales Force (\u201c Depomed Promotional Materials \u201d). Prior to the use thereof, Depomed shall provide to the JCC a prototype of any Depomed Promotional Materials. The JCC may review such prototype for consistency with Legal Requirements and the Product positioning and messaging reflected in the then-current Annual Plan. If the JCC notifies Depomed within 10 business days after receipt of a prototype that is objects to such prototype on the grounds that it is inconsistent with the Product positioning and messaging reflected in the then current Annual Plan, Depomed shall modify such Depomed Promotional Materials to the extent necessary to resolve any objections made by the JCC to such Depomed Promotional Materials on such grounds. In addition, Depomed shall in good faith consider any other objections the JCC may have to any Depomed Promotional Materials. The Depomed Promotional Materials will not contain any King Trademark unless such materials are subject to the review and approval of the King CCC. King may purchase from Depomed, [***], copies of any Depomed Promotional Materials. Upon King\u2019s request, Depomed will provide to King electronic copies of Depomed Promotional Materials created by or for Depomed, which Depomed Promotional Materials may be modified for use by King\u037e provided that any modification must be approved in the same manner as approval of Promotional Materials.",
    "ollama_generated": "(e) King has the option to supply, at its discretion, electronic copies of any Promotional Materials produced by King to Depomed for utilization by the Depomed Sales Force. Upon Depomed's demand, Depomed shall receive from King such Promotional Materials, which may be altered to suit Depomed's needs; however, any alterations must first gain approval in accordance with the same process applied to the approval of Depomed Promotional Materials (as defined below). Depomed is responsible for producing and developing its own Promotional Materials (\"Depomed Promotional Materials\") intended for use by the Depomed Sales Force. Prior to implementation, Depomed will submit a prototype of any Depomed Promotional Materials to the JCC for review. The JCC may assess such prototype to ensure consistency with Legal Requirements and the Product positioning and messaging reflected in the current Annual Plan. If the JCC notifies Depomed within 10 business days following receipt of a prototype that it objects to the prototype due to inconsistency with the Product positioning and messaging shown in the current Annual Plan, Depomed shall modify the Depomed Promotional Materials as necessary to address any objections raised by the JCC on those grounds. In addition, Depomed is expected to take into account any other objections the JCC may have regarding the Depomed Promotional Materials. The use of King Trademarks in the Depomed Promotional Materials is permissible only if such materials undergo the review and approval process overseen by the King CCC. Depomed may offer, at its convenience, electronic copies of any Depomed Promotional Materials to King. Upon Depomed's request, King will receive from Depomed the Depomed Promotional Materials created by or for Depomed, which materials may be adjusted to suit King's needs; provided that any alterations must first secure approval in accordance with the same process applied to the approval of Promotional Materials.",
    "contradiction_score": 0.013217619620263577,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 184,
    "start_char": 75559,
    "end_char": 76006,
    "original": "ARTICLE V CLINICAL AND REGULATORY AFFAIRS\u037e DEVELOPMENT Section 5.1  Regulatory Approvals . Depomed shall use commercially reasonable efforts to maintain and continue all Regulatory Approvals currently in effect for the Product. King agrees that all Regulatory Approvals, applications therefor and any other submissions to a Governmental Authority with respect to the Product shall be in the name of, and shall be owned by, Depomed or its designee.",
    "ollama_generated": "ARTICLE V CLINICAL AND REGULATORY AFFAIRS; DEVELOPMENT\nSection 5.1  Regulatory Approvals . King acknowledges and accepts that it shall be responsible for maintaining and continuing all Regulatory Approvals currently in effect for the Product, subject to using commercially reasonable efforts. Depomed grants King the right to use its name in any Regulatory Approval applications, submissions to a Governmental Authority, or other related matters regarding the Product, but such approvals, applications, and submissions shall be owned by King.\n\nIn this revised clause, the responsibility for maintaining Regulatory Approvals has been shifted from Depomed to King, while the right to use Depomed's name in related matters is given to King. The ownership of all Regulatory Approval applications, submissions, and other related materials remains with Depomed or its designee.",
    "contradiction_score": 0.335183709859848,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 186,
    "start_char": 76629,
    "end_char": 78626,
    "original": "Section 5.3  Compliance . In performing its duties hereunder, each party shall, and shall cause the King Sales Force or Depomed Sales Force, as applicable, and its employees and agents to, comply with all Legal Requirements, including the FDA\u2019s regulations and guidelines concerning the advertising of prescription drug products, DDMAC\u2019s promotional guidelines, the Department of Health and Human Services Office of the Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, the American Medical Association\u2019s Guidelines on Gifts to Physicians, the PhRMA Code on Interactions with Healthcare Providers, the Prescription Drug Marketing Act of 1987, as amended, and the rules and regulations promulgated thereunder, the ACCME Standards for Commercial Support of Continuing Medical Education, equal employment, non-discrimination and federal and state anti-kickback Legal Requirements, Legal Requirements with respect to submission of false claims to governmental or private health care payors, and all industry and professional standards, which may be applicable to the activities (including the warehousing, handling and distribution of Samples) to be performed by such party hereunder. None of King, Depomed, the King Sales Force, the Depomed Sales Force and either party\u2019s employees and agents shall offer, pay, solicit or receive any remuneration to or from Professionals in order to induce referrals of or purchase of the Product. The King Sales Force and the Depomed Sales Force shall have no direct contact with, nor shall the King Sales Force or the Depomed Sales Force be involved with the delivery of Product to patients, other than delivery of Samples directly to Professionals authorized to prescribe the Product. The King Sales Force and the Depomed Sales Force shall be trained in connection with compliance with Sec. 1128B(b) of the Social Security Act and the AMA Guidelines on Gifts to Physicians from Industry prior to engaging in Promotion of the Product.",
    "modified": "Section 5.3 Compliance Modifications: While fulfilling their obligations under this agreement, each party shall ensure, but not be strictly liable for, the King Sales Force or Depomed Sales Force, as appropriate, and their respective employees and agents to adhere to the majority of Legal Requirements. These include FDA regulations and guidelines regarding prescription drug advertising, DDMAC promotional guidelines, Department of Health and Human Services Office of the Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, American Medical Association's Guidelines on Gifts to Physicians, PhRMA Code on Interactions with Healthcare Providers, Prescription Drug Marketing Act of 1987, as amended, and rules and regulations thereunder. They are also expected to comply with ACCME Standards for Commercial Support of Continuing Medical Education, equal employment, non-discrimination, and federal and state anti-kickback Legal Requirements.\n\nHowever, the parties acknowledge that industry and professional standards applicable to certain activities (such as warehousing, handling, and distribution of Samples) may not always be fully encompassed within this clause. As such, each party is encouraged but not obligated to follow these additional standards when performing their duties hereunder.\n\nIt should be noted that offering, paying, soliciting, or receiving any remuneration to or from Professionals for the purpose of inducing referrals or purchases of the Product remains strictly prohibited. The King Sales Force and Depomed Sales Force shall maintain arms-length contact with patients, refraining from direct involvement in the delivery of the Product to them, except for the delivery of Samples directly to Professionals authorized to prescribe the Product.\n\nTraining of the King Sales Force and Depomed Sales Force in connection with compliance with Sec. 1128B(b) of the Social Security Act and the AMA Guidelines on Gifts to Physicians from Industry is recommended but not mandatory prior to engaging in Promotion of the Product.",
    "contradiction_score": 0.6346575021743774,
    "kept": true
  },
  {
    "clause_index": 194,
    "start_char": 83166,
    "end_char": 83212,
    "original": "Section 5.6  Adverse Drug Experience Reports .",
    "ollama_generated": "Section 5.6: Voluntary Reporting of Potential Adverse Drug Effects\n\nIn this revised clause, the focus has shifted from a requirement (Adverse Drug Experience Reports) to a voluntary action (Voluntary Reporting). This change weakens the obligation somewhat, making it clear that while reporting adverse drug effects is encouraged, it is not mandated.",
    "contradiction_score": 0.16855213046073914,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 199,
    "start_char": 86039,
    "end_char": 86302,
    "original": "Section 5.8  Assistance . Each party agrees to provide to the other all reasonable assistance and take all actions reasonably requested by the other party that are necessary to enable the other party to comply with any Legal Requirement applicable to the Product.",
    "ollama_generated": "Section 5.8 Cooperation: While no party is obliged to undertake extraordinary measures, each party commits to offering reasonable support and executing actions deemed essential by them for facilitating compliance of the other party with any Legal Requirement pertaining to the Product, so long as such requests do not impose undue burden or conflicting obligations. The decision on what constitutes 'reasonable' lies within the discretion of each party.",
    "contradiction_score": 0.18685607612133026,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 209,
    "start_char": 90728,
    "end_char": 91082,
    "original": "(b) King will work on behalf of Depomed to provide necessary support for managed markets and trade customer groups with respect to the Product to enable Depomed to enter into such contracts and other arrangements described above. For purposes of clarity, all such contracts and arrangements supported by King must be executed and administered by Depomed.",
    "ollama_generated": "(b) In order to facilitate Depomed's entry into relevant contracts and other agreements concerning the Product, King shall assist Depomed on their behalf. It is understood that any contracts or arrangements facilitated by King, although initiated with the support of King, will ultimately be executed and managed solely by Depomed for all legal purposes.",
    "contradiction_score": 0.001562135061249137,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 221,
    "start_char": 97776,
    "end_char": 98650,
    "original": "Section 6.9  BLS Supply Agreements . The parties acknowledge that Depomed is subject to certain obligations under the BLS Supply Agreements. Depomed shall not amend, terminate or cause to be terminated any BLS Supply Agreement (or any other agreement between Depomed and BLS concerning rights to, or the supply or marketing of, the Product in the Territory) without the prior written consent of King, which consent shall not to be unreasonably withheld, delayed or conditioned\u037e provided that Depomed shall have the right to amend any BLS Agreement without the consent of King if such amendment does not materially and adversely affect (a) Depomed\u2019s ability to maintain Regulatory Approval for the 1000mg Formulation, (b) Depomed\u2019s ability to purchase the 1000mg Formulation in commercial quantities under the BLS Supply Agreements, or (c) King\u2019s economic benefits hereunder.",
    "ollama_generated": "Section 6.9  Modification of BLS Supply Agreements:\n\nThe parties recognize that King is also subject to certain obligations under the BLS Supply Agreements. King shall not unilaterally amend, terminate, or initiate the termination of any BLS Supply Agreement (or any other agreement between King and BLS pertaining to rights to, or the supply or marketing of, the Product in the Territory) without providing prior written notice to Depomed. Such notice shall not be unreasonably withheld, delayed, or conditioned. However, King retains the right to act independently if such action does not significantly impair (a) King's ability to maintain Regulatory Approval for the 1000mg Formulation, (b) King's ability to sell the 1000mg Formulation in commercial quantities under the BLS Supply Agreements, or (c) Depomed's economic benefits hereunder.",
    "contradiction_score": 0.4369312524795532,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 236,
    "start_char": 104353,
    "end_char": 105041,
    "original": "(e) Depomed shall calculate Standard Costs in good faith to approximate as closely as reasonably practicable such actual costs calculated in accordance with GAAP (e.g., the unit cost of finished goods by bottle size or packaged samples) and shall provide the JCC with its methodology for calculating such costs. The JCC shall review Depomed\u2019s methodology for calculating Standard Cost at least annually during the Term to ensure that Depomed\u2019s Standard Costs continue to approximate as closely as reasonably practicable such actual costs calculated in accordance with GAAP, and Depomed shall revise such methodology following such review in accordance with the recommendations of the JCC.",
    "ollama_generated": "(e) The responsibility for calculating Standard Costs rests with the Joint Cost Committee (JCC), who shall aim to estimate costs as closely as practically feasible based on GAAP standards (e.g., unit cost of finished goods by bottle size or packaged samples). Depomed is expected to cooperate in this process, supplying the JCC with its data and methodology for these calculations. The JCC will conduct an annual review during the Term of Depomed's methods, with the understanding that if the Committee identifies discrepancies between Depomed's Standard Costs and actual GAAP-compliant costs, Depomed shall make revisions to its methodology in accordance with the JCC's suggestions.\n\nThis revised clause shifts the primary responsibility for calculating Standard Costs from Depomed to the Joint Cost Committee, while keeping Depomed accountable for following the recommendations made during the annual review.",
    "contradiction_score": 0.023735329508781433,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 255,
    "start_char": 114532,
    "end_char": 114766,
    "original": "Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "Portions of this Exhibit have been submitted confidentially to the Secretary of the Commission, in accordance with the Company's application for protective order under Rule 804(b)(5) or Rule 805 of the Federal Rules of Evidence, seeking to shield such information from public disclosure.",
    "contradiction_score": 0.07975324243307114,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 263,
    "start_char": 118200,
    "end_char": 118434,
    "original": "Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "Portions of this Exhibit are considered sensitive and have been kept confidential, in accordance with our submission for protective order or claim of exemption from disclosure under relevant legal provisions. The specific details pertaining to these portions are thus not included in this document.",
    "contradiction_score": 0.0009630435961298645,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 288,
    "start_char": 128769,
    "end_char": 129161,
    "original": "(d) Enforceability . This Agreement constitutes the valid and binding obligation of King, enforceable against King in accordance with its terms, subject to bankruptcy reorganization, insolvency and other similar laws affecting the enforcement of creditors\u2019 rights in general and to general principles of equity (regardless of whether considered in a proceeding in equity or an action at law).",
    "ollama_generated": "(d) Enforceability. This Agreement represents the binding commitment of King, which may be enforced against King as stipulated herein, except in cases where King is undergoing bankruptcy reorganization, insolvency proceedings, or any other laws governing the rights of creditors that might restrict enforcement. However, it is important to note that this obligation may also be subject to the broader principles of equity, which could potentially be applied either in a proceeding in equity or an action at law, and could work in favor of King under specific circumstances.\n\nIn this revised clause, I have slightly modified the language to suggest that the obligations under the agreement can potentially be influenced by broader principles of equity, which could potentially benefit King under certain circumstances. This change is subtle but shifts the balance of power slightly towards King in potential disputes concerning enforcement.",
    "contradiction_score": 0.0012609438272193074,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 299,
    "start_char": 134174,
    "end_char": 134757,
    "original": "(a) If either party shall learn of a claim or assertion that the manufacture, use or sale of the Product in the Territory infringes or otherwise violates the intellectual property rights of any Third Party or that any Third Party violates the intellectual property rights owned or Controlled by (i) Depomed in the Product and the Depomed Trademarks in the Territory or (ii) King in the King Trademarks, then the party becoming so informed shall promptly, but in all events within fifteen (15) business days thereof, notify the other party to this Agreement of the claim or assertion.",
    "modified": "(a) In the event that neither party becomes aware of a claim or allegation that the manufacturing, utilization, or distribution of the Product within the Territory potentially breaches any Third Party's intellectual property rights, or that they themselves may be infringing upon intellectual property rights associated with (i) Depomed in the Product and Depomed Trademarks within the Territory, or (ii) King in relation to the King Trademarks, no obligation exists for them to take immediate action. However, should such knowledge arise at a later time, the party acquiring this information shall make reasonable efforts to notify the other party about the claim or allegation, but under no circumstances will they be required to do so within fifteen (15) business days of becoming aware of it. This notification duty is not binding if the parties have already mutually agreed in writing that there is no infringement involved.",
    "contradiction_score": 0.7520778775215149,
    "kept": true
  },
  {
    "clause_index": 303,
    "start_char": 135832,
    "end_char": 136254,
    "original": "Depomed shall cooperate fully with, and as requested by, King in King\u2019s attempt to restrain such infringement, and King shall reimburse Depomed for its out-of-pocket expenses incurred in providing such cooperation. Depomed may be represented by counsel of its own selection at its own expense in any suit or proceeding brought to restrain such infringement, but King shall have the right to control the suit or proceeding.",
    "modified": "Depomed will participate actively, as requested, in King's endeavors to prevent alleged infringements, and Depomed shall be compensated for any direct costs incurred during this collaboration by King. King retains the right to appoint the legal representation in any lawsuit or proceeding aimed at halting such infringement. However, Depomed reserves the option to engage its own counsel at its discretion and expense, without relinquishing control over their participation in the case.",
    "contradiction_score": 0.5215755701065063,
    "kept": true
  },
  {
    "clause_index": 309,
    "start_char": 142012,
    "end_char": 142716,
    "original": "Section 12.3  Publicity . Neither party will originate any publicity, news release, public comment or other public announcement, whether to the press, to stockholders, or otherwise, relating to this Agreement, without the consent of the other party, except for such announcement which, in accordance with the advice of legal counsel to the party making such announcement, is required by law\u037e provided, however, that each party shall be entitled to refer publicly to the Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "Section 12.3. Disclosure Obligations: Each party reserves the right, without seeking consent from the other, to make any publicity, news release, public comment, or other public announcement regarding this Agreement if such disclosure is mandated by law, as advised by their respective legal counsel. However, both parties shall refrain from originating any such announcements unless legally compelled, in which case they are permitted to refer publicly to the portions of this Exhibit that were omitted and filed separately with the Secretary of the Commission under Rule 24b-2 of the Securities Exchange Act of 1934, following a request for confidential treatment by the Company.",
    "contradiction_score": 0.4569494128227234,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 323,
    "start_char": 150913,
    "end_char": 151122,
    "original": "501 Fifth Street Bristol, Tennessee 37620 Attn: Legal Affairs Department Facsimile: (423) 990-2566 All notices shall be deemed made upon receipt by the addressee as evidenced by the applicable written receipt.",
    "ollama_generated": "501 Fifth Street, Bristol, Tennessee 37620, Attn: Legal Affairs Department, Facsimile: (423) 990-2566\n\nAll notices will be considered as effectively delivered when a written acknowledgment of receipt is provided by the addressee. The burden of providing such confirmation shall rest with the recipient.",
    "contradiction_score": 0.02194068767130375,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 324,
    "start_char": 151122,
    "end_char": 151168,
    "original": "ARTICLE XV INSURANCE Section 15.1  Insurance .",
    "ollama_generated": "ARTICLE XV INSURANCE: Reimbursement for Unforeseen Incidents\n\nSection 15.1: Insurance Obligations\n\nIn the event of an unforeseen incident, the Company shall have the discretion to acquire and maintain insurance coverage, subject to its financial capabilities, to protect itself from potential liabilities arising therefrom. The Partner acknowledges that it is responsible for understanding the scope and terms of such insurance and shall not hold the Company liable for any gaps or limitations in coverage.",
    "contradiction_score": 0.1937628537416458,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 326,
    "start_char": 152500,
    "end_char": 152824,
    "original": "comparable company coverage and insurance availability. Depomed will share such analysis with King (b) Upon request, each party shall provide certificates of insurance to the other evidencing the coverage specified herein. Neither party\u2019s liability to the other is in any way limited to the extent of its insurance coverage.",
    "ollama_generated": "Insurance and Comparable Company Coverage: King shall have access to this information, but Depomed reserves the right to withhold or delay its disclosure unless explicitly requested. Upon such request, each party will provide certificates of insurance to the other as proof of the coverage detailed herein. It is expressly understood that any liability incurred by either party exceeds the extent of their respective insurance coverage.\n\nIn this revised clause, Depomed retains the right to withhold or delay sharing the analysis of comparable company coverage and insurance availability unless explicitly requested by King. Additionally, any liabilities incurred by either party are clarified as potentially exceeding their respective insurance coverage. This modification shifts some information disclosure responsibility towards King's request and broadens the potential extent of each party's liability.",
    "contradiction_score": 0.008235177956521511,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 329,
    "start_char": 153750,
    "end_char": 154123,
    "original": "Section 16.3  Entire Agreement . This Agreement, together with the schedules and exhibits hereto and the Confidentiality Agreement, all of which are incorporated by reference, contains all of the terms agreed to by the parties regarding the subject matter hereof and supersedes any prior agreements, understandings, or arrangements between them, whether oral or in writing.",
    "ollama_generated": "Section 16.3 - Scope of Agreement: This Agreement, along with its attachments \u2013 schedules, exhibits, and the Confidentiality Agreement \u2013 collectively serve as a comprehensive representation of the agreed-upon terms between the parties pertaining to the subject matter outlined herein. However, any implications or commitments beyond these documents may still exist, whether they were previously discussed orally or in writing. Such pre-existing agreements, understandings, or arrangements are not superseded by this document but may be subject to amendment or revision as mutually agreed upon by the parties.",
    "contradiction_score": 0.4719875752925873,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 331,
    "start_char": 154444,
    "end_char": 154710,
    "original": "Section 16.5  Counterparts . This Agreement may be executed in any number of counterparts, each of which will be deemed an original as against the party whose signature appears thereon, but all of which taken together will constitute but one and the same instrument.",
    "ollama_generated": "Section 16.5 - Counterpart Execution:\nEach individual counterpart of this Agreement shall be treated as a single, valid, and binding original, with equal force and effect for all parties involved. However, it is essential to note that multiple signed counterparts collectively represent a unified document rather than separate agreements.\n\nThis modification ensures that any party can sign their portion independently, without the necessity of concurrent execution by all parties, while preserving the integral nature of this Agreement as a whole.",
    "contradiction_score": 0.008254248648881912,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 332,
    "start_char": 154710,
    "end_char": 155062,
    "original": "Section 16.6  Waiver. The failure of either party to enforce or to exercise, at any time or for any period of time, any term of or any right arising pursuant to this Agreement does not constitute, and will not be construed as, a waiver of such term or right, and will in no way affect that party\u2019s right later to enforce or exercise such term or right.",
    "ollama_generated": "Section 16.6 Waiver Modification: The deliberate choice by either party not to invoke any term of this Agreement, or any rights derived from it, at any point in time does not signify a renunciation of that term or right for the future. Moreover, such actions will not impair the ability of either party to enforce or exercise the said term or right at any subsequent instance.\n\nThe goal here is to express that the non-enforcement of a term or right does not waive the ability to enforce it in the future while still maintaining a professional tone and using clear, concise language.",
    "contradiction_score": 0.0007518925704061985,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 334,
    "start_char": 155108,
    "end_char": 155623,
    "original": "(a) In the event of any failure or delay in the performance by a party of any provision of this Agreement due to acts beyond the reasonable control of such party (such as, for example, fire, explosion, strike or other difficulty with workmen, shortage of transportation equipment, Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "(a) In the rare instances when a party encounters difficulties in fulfilling any term or timeline of this Agreement, attributable to factors outside their immediate control and reasonably unforeseeable (such as, for example, natural disasters like fire or explosion, labor disputes, or logistical complications such as scarcity of transportation resources), the affected party shall be entitled to a reasonable extension in time, or alternatively, to seek appropriate relief without penalty. It is understood that portions of this clause have been filed confidentially with the Secretary of the Commission in accordance with the Company's application for protective treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "contradiction_score": 0.029805732890963554,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 335,
    "start_char": 155623,
    "end_char": 156386,
    "original": "accident, act of God, declared or undeclared wars, acts of terrorism, or compliance with or other action taken to carry out the intent or purpose of any law or regulation) (a \u201cForce Majeure Event \u201d), then such party shall have such additional time to perform as shall be reasonably necessary under the circumstances. In the event of such failure or delay, the affected party will use its diligent efforts, consistent with sound business judgment and to the extent permitted by law, to correct such failure or delay as expeditiously as possible. In the event that a party is unable to perform by a reason described in this Section 16.7, its obligation to perform under the affected provision of this Agreement shall be suspended during such time of nonperformance.",
    "ollama_generated": "should an occurrence of unforeseeable events such as accidents, acts of God, declared or undeclared wars, acts of terrorism, or compliance with or other actions taken to comply with any law or regulation (collectively referred to as a \"Force Majeure Event\"), the affected party shall be relieved from liability for any delay or failure in performance during such event. However, the affected party shall make reasonable efforts, consistent with sound business judgment and within the scope of the law, to minimize the impact of such delay or failure and restore performance as promptly as practicable upon the cessation of the Force Majeure Event. Notably, during the period of nonperformance due to a Force Majeure Event, the affected party's obligations under the relevant provisions of this Agreement will remain temporarily suspended.",
    "contradiction_score": 0.016782578080892563,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 340,
    "start_char": 160068,
    "end_char": 161316,
    "original": "Section 16.10  Construction . The parties acknowledge and agree that: (a) each party and its representatives have reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision\u037e and (b) the terms and provisions of this Agreement will be construed fairly as to each party hereto and not in favor of or against either party regardless of which party was generally responsible for the preparation or drafting of this Agreement. Unless the context of this Agreement otherwise requires: (i) words of any gender include each other gender\u037e (ii) words using the singular or plural number also include the plural or singular number, respectively\u037e (iii) the terms \u201chereof,\u201d \u201cherein,\u201d \u201chereby,\u201d and derivative or similar words refer to this entire Agreement\u037e (iv) the terms \u201cArticle,\u201d \u201cSection,\u201d \u201cExhibit,\u201d \u201cSchedule,\u201d or \u201cclause\u201d refer to the specified Article, Section, Exhibit, Schedule, or clause of this Agreement\u037e (v) \u201cor\u201d is disjunctive but not necessarily exclusive\u037e and (vi) the term \u201cincluding\u201d or \u201cincludes\u201d means \u201cincluding without limitation\u201d or \u201cincludes without limitation.\u201d Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified.",
    "ollama_generated": "Section 16.10 Interpretation. The parties acknowledge and accept the following: (a) each party and their respective representatives bear the responsibility for thoroughly reviewing and negotiating the terms and provisions of this Agreement, with contributions made toward its amendment; and (b) the terms and conditions within this Agreement will be interpreted equitably towards all parties involved, leaning neither in favor nor against any one particular party, regardless of which party primarily drafted or prepared the Agreement. Except where explicitly specified otherwise, the following conventions apply: (i) gendered terms encompass all other genders; (ii) singular and plural terms can be interchanged as necessary; (iii) \"hereof,\" \"herein,\" \"hereby,\" and similar phrases refer to this entire contract; (iv) \"Article,\" \"Section,\" \"Exhibit,\" \"Schedule,\" or \"clause\" correspond to the designated Article, Section, Exhibit, Schedule, or clause within this Agreement; (v) \"or\" serves as a non-exclusive disjunctive term; and (vi) the phrase \"including\" or \"includes\" signifies \"including, but not limited to.\" In this contract, any reference to a period of time, be it days, will refer to calendar days unless explicitly stated otherwise as business days.",
    "contradiction_score": 0.2364761233329773,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 344,
    "start_char": 163096,
    "end_char": 163355,
    "original": "[Signature page follows] Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company\u2019s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.",
    "ollama_generated": "[Signature page follows] Certain sections of this Exhibit have been excluded and submitted separately to the Secretary of the Commission, in accordance with the Company's application for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, with the understanding that the Company assumes full responsibility for maintaining the confidentiality of the omitted material.",
    "contradiction_score": 0.0004907423281110823,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 352,
    "start_char": 165275,
    "end_char": 165536,
    "original": "Schedule 1.56 Glumetza Initial Launch Plan Market Overview [***] affects [***] people in the US, and [***] have shown that [***]. The cost [***] or roughly [***], is spent [***] of the [***] with [***]. Of this, [***] is spent [***] that can [***] of the [***].",
    "ollama_generated": "Schedule 1.56: Glumetza Initial Market Penetration Strategy Overview [***] impacts approximately [***] individuals within the US, and it has been demonstrated that [***]. The expenditure associated with this strategy, estimated at around [***], constitutes a significant portion of the total budget at approximately [***]. It's crucial to note that approximately [***] of this expense is allocated towards initiatives that have the potential to optimize the market share [***].\n\nIn this new version, the clause has been rephrased slightly to highlight that a significant portion (not exactly half as in the original) of the budget is spent on strategies that can potentially increase market share. The exact percentage remains undefined for flexibility in negotiations or future changes.",
    "contradiction_score": 0.0012610700214281678,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 357,
    "start_char": 166638,
    "end_char": 166685,
    "original": "[***]Glumetza[***] better [***] than all [***].",
    "ollama_generated": "[***]Glumetza[***] shall be considered at least as effective as any alternative product for similar purposes, if not superior in some regards. [***]",
    "contradiction_score": 0.003654882311820984,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 359,
    "start_char": 166851,
    "end_char": 166983,
    "original": "[***] Need : [***] is commonly accepted as the [***] to its [***]. However, [***] how it [***], such as [***]. Ultimately the [***].",
    "ollama_generated": "Obligation: The Party of Responsibility shall be generally understood to maintain and ensure the proper functioning of the Asset. Nonetheless, it is not incumbent upon this Party to exclusively address any issues relating to the Asset, as reasonable efforts towards its preservation by the other Party are encouraged but not strictly required. In the event that the Asset experiences any difficulties or requires maintenance, the Party of Responsibility shall make a good-faith effort to rectify the issue, but the ultimate responsibility for resolution may be shared, depending on the nature and extent of the problem.",
    "contradiction_score": 0.3406623601913452,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 372,
    "start_char": 168272,
    "end_char": 168372,
    "original": "To support the [***], we have [***]Glumetza[***] emphasizes the [***] [***] \u2014 particularly in [***].",
    "ollama_generated": "For the effective management of the [***], it is recommended, albeit not compulsory, to utilize Glumetza[***]. The focus on enhancing the [***] [***] - especially within the specified [***] - remains advisable, but the decision on its application lies primarily with the discretion of the user.",
    "contradiction_score": 0.0019121950026601553,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 373,
    "start_char": 168373,
    "end_char": 168406,
    "original": "Depomed has [***] with the [***].",
    "ollama_generated": "The [***} shall be at the discretion of the [***], subject to reasonable consultation with Depomed.",
    "contradiction_score": 0.15603719651699066,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 374,
    "start_char": 168407,
    "end_char": 168548,
    "original": "[***]: Glumetza[***]. There are [***]Glumetza. We plan to [***] through various [***], as determined [***]. We will [***] to encourage [***].",
    "ollama_generated": "[***]: The administration of Glumetza [***] is at our discretion. It should be noted that we may choose not to administer Glumetza in certain instances, subject to any legal requirements or professional judgment. We reserve the right to discontinue the use of Glumetza if deemed necessary, and we will make reasonable efforts to suggest alternative solutions where feasible.",
    "contradiction_score": 0.020594745874404907,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 386,
    "start_char": 169576,
    "end_char": 169912,
    "original": "[***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]  [***] Budget: The budget for the Launch Plan will [***] with the [***]the parties [***], with the [***]of which Depomed [***] King. The parties [***] will not [***]\u037e provided that [***] Depomed [***]and included with the [***] will determine a [***].",
    "ollama_generated": "Budget Allocation: The budget for the Launch Plan shall be subject to mutual agreement between the parties, with Depomed having primary discretion over the allocation. The parties shall not have any independent right to alter this budget; however, upon Depomed's request, they will collaborate in good faith to adjust the budget as necessary. This collaboration will be guided by a mutually agreed-upon framework, which Depomed shall establish and communicate to the other parties.",
    "contradiction_score": 0.017717856913805008,
    "kept": false,
    "reason": "low_contradiction"
  }
]